PL2768484T3 - Liofilizowane liposomy - Google Patents

Liofilizowane liposomy

Info

Publication number
PL2768484T3
PL2768484T3 PL12841616T PL12841616T PL2768484T3 PL 2768484 T3 PL2768484 T3 PL 2768484T3 PL 12841616 T PL12841616 T PL 12841616T PL 12841616 T PL12841616 T PL 12841616T PL 2768484 T3 PL2768484 T3 PL 2768484T3
Authority
PL
Poland
Prior art keywords
lyophilized liposomes
liposomes
lyophilized
Prior art date
Application number
PL12841616T
Other languages
English (en)
Inventor
Donna Cabral-Lilly
Lawrence Mayer
Paul Tardi
David Watkins
Yi Zeng
Original Assignee
Jazz Pharmaceuticals Research Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2768484(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Research Llc filed Critical Jazz Pharmaceuticals Research Llc
Publication of PL2768484T3 publication Critical patent/PL2768484T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
PL12841616T 2011-10-21 2012-10-15 Liofilizowane liposomy PL2768484T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes
EP12841616.1A EP2768484B1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Publications (1)

Publication Number Publication Date
PL2768484T3 true PL2768484T3 (pl) 2019-12-31

Family

ID=48141268

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12841616T PL2768484T3 (pl) 2011-10-21 2012-10-15 Liofilizowane liposomy

Country Status (22)

Country Link
US (5) US10028912B2 (pl)
EP (2) EP3572071A1 (pl)
JP (6) JP6133308B2 (pl)
KR (5) KR102284689B1 (pl)
CN (2) CN104114156A (pl)
AU (1) AU2012326370C9 (pl)
BR (1) BR112014009305B1 (pl)
CA (1) CA2852777C (pl)
DK (1) DK2768484T3 (pl)
ES (1) ES2750368T3 (pl)
FR (1) FR19C1063I2 (pl)
HR (1) HRP20191683T1 (pl)
HU (2) HUE045978T2 (pl)
IL (1) IL232161B (pl)
LU (1) LUC00135I2 (pl)
NL (1) NL301016I2 (pl)
NO (1) NO2019041I1 (pl)
PL (1) PL2768484T3 (pl)
PT (1) PT2768484T (pl)
RU (1) RU2648753C2 (pl)
SI (1) SI2768484T1 (pl)
WO (1) WO2013059133A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852777C (en) * 2011-10-21 2020-10-27 Celator Pharmaceuticals Inc. Lyophilized liposomes
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
WO2016033380A1 (en) 2014-08-28 2016-03-03 The General Hospital Corporation Compositions and methods for treatment of neurological disorders
DK3283045T3 (da) * 2015-04-13 2021-05-10 Fountain Tech International Llc Et-trins-fremgangsmåde til fremstilling af ultrasmå lipidstrukturer
ES2862191T3 (es) 2015-07-22 2021-10-07 Nitto Denko Corp Composiciones y métodos para formas de liófilos de nanopartículas
CA3219061A1 (en) 2015-11-11 2017-05-18 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
EP3419572A4 (en) 2016-02-26 2019-09-25 The General Hospital Corporation SYSTEMS AND METHOD FOR THE PRODUCTION AND OUTPUT OF MEDICAL ICEBREAS
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN111093623A (zh) * 2017-07-10 2020-05-01 免疫疫苗技术公司 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途
MX2021003527A (es) 2018-09-25 2021-05-27 Celator Pharmaceuticals Inc Tratamiento de baja intensidad de trastornos hematologicos.
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
AU2020302784A1 (en) * 2019-06-28 2022-01-20 Board Of Regents, The University Of Texas System Method of reconstituting liposomal Annamycin
WO2021016457A1 (en) * 2019-07-24 2021-01-28 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术（石家庄）有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPS62501631A (ja) * 1985-01-11 1987-07-02 ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア リポソ−ムの保持法
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
JP2792702B2 (ja) * 1988-10-05 1998-09-03 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 乾燥時に改善された安定性を示すリポソームの調製方法
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
ATE237362T1 (de) * 1996-02-19 2003-05-15 Amersham Health As Thermostabilisiertes kontrastmittel
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
IL147559A0 (en) 1999-07-16 2002-08-14 Alza Corp A liposome composition having resistance to freeze/thaw damage
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ATE475411T1 (de) 2001-10-03 2010-08-15 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
AU2002340670A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
CA2536612A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination compositions of camptothecins and fluoropyrimidines
PT1744764E (pt) 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Formulações lipossómicas de agentes antraciclina e análogos de citidina
US7893338B2 (en) 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
EP1809254A2 (en) * 2004-10-28 2007-07-25 Alza Corporation Lyophilized liposome formulations and method
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
CA2587741A1 (en) 2004-11-18 2006-05-26 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
SI3300601T1 (sl) * 2007-02-16 2022-05-31 Rotalec Ip Holdings Llc Fiksna razmerja med zdravili za zdravljenje vrst hematopoetskega raka in proliferativnih motenj
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
EP2344161B1 (en) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
DK2508170T3 (en) 2009-12-03 2015-09-21 Jiangsu Hengrui Medicine Co LIPOSOM OF IRINOTECAN OR ITS HYDROCHLORIDE AND ITS PROCEDURE
EP2531175A2 (en) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
CA2852777C (en) * 2011-10-21 2020-10-27 Celator Pharmaceuticals Inc. Lyophilized liposomes

Also Published As

Publication number Publication date
AU2012326370B2 (en) 2017-06-01
US20210169803A1 (en) 2021-06-10
HUS1900047I1 (hu) 2019-11-28
KR20190111139A (ko) 2019-10-01
HRP20191683T1 (hr) 2019-12-13
CN108853031A (zh) 2018-11-23
SI2768484T1 (sl) 2019-12-31
AU2012326370A2 (en) 2014-06-12
JP6133308B2 (ja) 2017-05-24
US20180161273A1 (en) 2018-06-14
EP2768484B1 (en) 2019-07-24
RU2648753C2 (ru) 2018-03-28
JP2020007367A (ja) 2020-01-16
NL301016I2 (nl) 2020-04-16
LUC00135I2 (pl) 2021-02-12
RU2014120475A (ru) 2015-11-27
NO2019041I1 (no) 2019-11-25
US10835492B2 (en) 2020-11-17
KR102024836B1 (ko) 2019-09-24
IL232161A0 (en) 2014-05-28
CA2852777C (en) 2020-10-27
EP3572071A1 (en) 2019-11-27
JP2018150342A (ja) 2018-09-27
CN104114156A (zh) 2014-10-22
WO2013059133A1 (en) 2013-04-25
BR112014009305A2 (pt) 2017-04-11
FR19C1063I2 (fr) 2020-10-30
RU2018107407A (ru) 2019-02-25
JP6592556B2 (ja) 2019-10-16
US20140255475A1 (en) 2014-09-11
KR20200057104A (ko) 2020-05-25
BR112014009305B1 (pt) 2023-01-24
AU2012326370A1 (en) 2014-06-05
EP2768484A1 (en) 2014-08-27
LUC00135I1 (pl) 2019-10-25
JP6359717B2 (ja) 2018-07-18
IL232161B (en) 2019-07-31
CA2852777A1 (en) 2013-04-25
EP2768484A4 (en) 2015-04-22
DK2768484T3 (da) 2019-10-07
JP2022033892A (ja) 2022-03-02
JP7476161B2 (ja) 2024-04-30
RU2018107407A3 (pl) 2021-05-04
US20190070112A1 (en) 2019-03-07
KR20140092323A (ko) 2014-07-23
FR19C1063I1 (fr) 2019-11-22
KR20210095746A (ko) 2021-08-02
KR102452305B1 (ko) 2022-10-07
HK1201039A1 (en) 2015-08-21
NL301016I1 (nl) 2019-10-30
KR102284689B1 (ko) 2021-08-02
KR102113753B1 (ko) 2020-05-21
JP2014532623A (ja) 2014-12-08
PT2768484T (pt) 2019-10-28
JP2024045183A (ja) 2024-04-02
US10166184B2 (en) 2019-01-01
ES2750368T3 (es) 2020-03-25
HUE045978T2 (hu) 2020-01-28
US10028912B2 (en) 2018-07-24
JP2017160211A (ja) 2017-09-14
AU2012326370C9 (en) 2023-05-18
AU2012326370C1 (en) 2023-03-30
KR20220141906A (ko) 2022-10-20
US20230172855A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
HUS1900047I1 (hu) Liofilizált liposzómák
ZA201307355B (en) Composite elements
ZA201306118B (en) Lyophilized formulations
AP2014007621A0 (en) 2-Thiopyrimidinones
PL2993263T3 (pl) Tkanina o bardzo wysokiej sprężystości
EP2691581A4 (en) joint assembly
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
EP2759709A4 (en) COMPRESSOR
GB201619994D0 (en) Improved fabric
GB2487250B (en) Compressor
GB201106391D0 (en) Novel composite
GB201106377D0 (en) Novel composite
GB201115014D0 (en) Peptides
GB201117700D0 (en) Improved fabric
PH32011000890S1 (en) Fabric
PH32011000888S1 (en) Fabric
PH32011000897S1 (en) Fabric
PH32011000894S1 (en) Fabric
PH32011000892S1 (en) Fabric
PH32011000891S1 (en) Fabric
GB201114292D0 (en) Fabric
PH32011000889S1 (en) Fabric
PH32011000885S1 (en) Fabric
PH32011000881S1 (en) Fabric